Pulmonary Embolism Market Report 2026

The pulmonary embolism market size has grown rapidly in recent years. It will grow from $2.26 billion in 2025 to $2.53 billion in 2026 at a compound annual growth rate (CAGR) of 12%. The growth in the historic period can be attributed to increasing incidence of cardiovascular and thromboembolic disorders, expansion of hospital emergency care services, wider use of anticoagulant medications, growing awareness of pulmonary embolism symptoms, availability of advanced diagnostic imaging.

The pulmonary embolism market size is expected to see rapid growth in the next few years. It will grow to $4.14 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to increasing investments in advanced anticoagulant drugs, rising adoption of catheter-based intervention techniques, expansion of early diagnostic screening programs, growing focus on outpatient management strategies, increasing demand for personalized cardiovascular care. Major trends in the forecast period include increasing adoption of novel anticoagulant therapies, rising use of minimally invasive thrombectomy devices, growing focus on early and accurate diagnosis, expansion of integrated care pathways, enhanced emphasis on risk stratification and prevention.

The rising prevalence of cancer is expected to drive the growth of the pulmonary embolism market going forward. Cancer refers to a group of diseases marked by uncontrolled and abnormal cell growth within the body. An increase in cancer cases elevates the risk of blood clot formation, including pulmonary embolism, among cancer patients. This, in turn, increases demand for diagnostic procedures and treatment options, including specialized therapeutic drugs. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases rose to 2,001,140, up from 1,958,310 in 2023, representing an increase of 2.19%. Therefore, the growing prevalence of cancer is contributing to the expansion of the pulmonary embolism market.

Major companies operating in the pulmonary embolism market are focusing on the development of innovative catheter-based solutions to strengthen their competitive position. Products such as the Triever16 Curve catheter and the RevCore thrombectomy catheter are designed to improve procedural efficiency and outcomes. For example, in June 2023, Inari Medical Inc., a US-based medical device company, introduced the Triever16 Curve catheter and the RevCore thrombectomy catheter. The Triever16 Curve catheter is intended for peripheral thrombectomy and pulmonary embolism procedures and is designed to be highly trackable with a pre-shaped curve that enables targeted aspiration. Its design also allows seamless access to larger and more powerful 20F or 24F catheters. The RevCore thrombectomy catheter is developed to treat venous in-stent thrombosis and functions as a mechanical thrombectomy device that uses a nitinol basket to capture and remove blood clots. Together, these catheter innovations enhance the safety and effectiveness of pulmonary embolism treatment procedures.

In February 2025, Stryker Corporation, a US-based medical technology company, acquired Inari Medical Inc. for an undisclosed amount. Through this acquisition, Stryker aims to strengthen its position in the rapidly growing peripheral vascular market and broaden its cardiovascular product portfolio. Inari Medical Inc. is a US-based company known for providing pulmonary embolism treatments through its FlowTriever system.

Major companies operating in the pulmonary embolism market are Pfizer Inc., Johnson And Johnson Private Limited, F Hoffmann La Roche Ltd., Merck And Co Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK plc, Abbott Laboratories, AstraZeneca plc, Medtronic plc, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals plc, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd., CSL Behring GmbH, Grifols S.A., Octapharma AG, Kedrion S.p.A.

North America was the largest region in the pulmonary embolism market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary embolism market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pulmonary embolism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the pulmonary embolism market by increasing costs of imported anticoagulant drugs, diagnostic imaging equipment, catheter-based devices, and medical consumables. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported medical technologies, while Asia-Pacific faces cost pressure in pharmaceutical manufacturing and device exports. These tariffs are increasing treatment and diagnostic costs. However, they are also supporting domestic pharmaceutical production, regional medical device manufacturing, and localized supply chain development for cardiovascular care solutions.

The pulmonary embolism market research report is one of a series of new reports that provides pulmonary embolism market statistics, including pulmonary embolism industry global market size, regional shares, competitors with a pulmonary embolism market share, detailed pulmonary embolism market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary embolism industry. This pulmonary embolism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pulmonary embolism is a medical condition characterized by a blockage in the pulmonary artery, which carries blood from the heart to the lungs. This blockage is usually caused by a blood clot that travels to the lungs from another part of the body, most often the legs. Symptoms of pulmonary embolism can vary depending on the size and severity of the clot and may include sudden shortness of breath, chest pain, coughing up blood or blood-streaked mucus, and other related signs.

The primary treatment options for pulmonary embolism include medications, mechanical devices, surgical interventions, and other approaches. Medications are substances used for the treatment, management, prevention, or relief of medical conditions and diseases. Pulmonary embolism is diagnosed using several techniques, such as chest X-ray, electrocardiogram (ECG), magnetic resonance imaging (MRI), computed tomography scans, pulmonary angiography, venography, venous ultrasound, D-dimer testing, and other diagnostic methods. Common symptoms include shortness of breath, chest pain, cough, irregular heartbeat, dizziness, fever, cyanosis, and others. Drugs for pulmonary embolism are mainly distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels, and the key end users include hospitals, specialty clinics, homecare settings, and others.

The pulmonary embolism market consists of revenues earned by entities by providing services such as medical management, thrombolytic therapy, monitoring and oxygen therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The pulmonary embolism market also includes sales of diagnostic imaging equipment, oxygen delivery devices, interventional devices, medical alert systems and pulse oximeters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.